MAX
Chart Tema Oncology ETF
Simple chart
Extended chart
Main settings
| Annual return | 46.73 |
| Asset size | Multi-Cap |
| Asset type | Equity |
| Average P/E | 7.05 |
| Beta | 2.41 |
| Commission | 0.75 |
| Country | USA |
| Currency | usd |
| Div. yield | 0.74 |
| Focus | Health Care |
| Foundation date | Aug 15. 2023 |
| ISO country | US |
| Index | ACTIVE - No Index |
| Number of companies | 44 |
| Owner | Tema Global Ltd. |
| Region | Global |
| Region | Broad |
| Strategy | Active |
| Top 10 issuers, % | 43.31 |
| Website | link |
| segment | Equity: Global Pharma, Biotech & Life Sciences |
| Change per day | 0% 37.5327 $ |
| Change per week | +1.63% 36.929 $ |
| Change per month | +2.91% 36.47 $ |
| Change per 3 month | +7.6% 34.882 $ |
| Change per half year | +24.57% 30.131 $ |
| Change per year | +46.73% 25.58 $ |
| Change per year to date | +2.89% 36.48 $ |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Top companies
| Title | Industry | Share, % | P/BV | P/S | P/E | EV/Ebitda | Dividend yield | |
| #1 |
 Revolution Medicines, Inc. |
Healthcare | 6.6155 | 3.24 | 282.39 | -9.86 | -11.76 | 0 |
| #2 |
 BridgeBio Pharma, Inc. |
Healthcare | 5.0013 | -3.5 | 23.01 | -17.05 | -14.09 | 0 |
| #3 |
 Novan, Inc. |
Healthcare | 4.9735 | 6.65 | 1.3 | 14.9 | -0.66 | 0 |
| #4 |
 AstraZeneca PLC |
Healthcare | 4.7471 | 10.03 | 7.58 | 58.27 | 28.15 | 3.79 |
| #5 |
 Eli Lilly and Company |
Healthcare | 4.3883 | 49.02 | 14.17 | 44.77 | 47.94 | 0.67 |
| #6 |
 Bristol-Myers |
Healthcare | 4.2611 | 6.93 | 2.35 | -10.55 | 48.77 | 4.75 |
| #7 |
 Merck & Co |
Healthcare | 3.9503 | 5.39 | 3.9 | 14.6 | 10.65 | 3.01 |
| #8 |
 Nuvalent, Inc. |
Healthcare | 3.3467 | 4.86 | 0 | -19.93 | -18.02 | 0 |
| #9 |
 Genmab A/S |
Healthcare | 3.2038 | 2.62 | 4.47 | 12.26 | 9.01 | 0 |
| #10 |
 Immunome |
Healthcare | 2.8265 | 3.44 | 68.88 | -2 | -3.2 | 0 |
Similar ETF
Other ETFs from the Management Company
| Title | Class | Category | Commission | Annual return |
| Equity | 0.75 | 42.76 |
Description Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Based on sources: porti.ru
